CompoundsActive IngredientsGefitinib CAS 184475-35-2

SKU: WGP-184475-35-2-1

Gefitinib CAS:184475-35-2

Molecular Formula: C22H24ClFN4O3
Molecular Weight: 446.9
Availability: On Order
Packaging: Regular packaging or customised

Contact us directly for more

Telegram Telegram Signal Signal Threema Threema
  • Description
  • Our Policy


Gefitinib CAS 184475-35-2  Product Information

Product Name: Gefitinib
Synonyms: Iressa;N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide;MFCD04307832;Irressat;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amin;N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]chinazolin-4-amin;N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)chinazolin-4-amin;N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine;N-(3-chloro-4-fluorophényl)-7-méthoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;ZD-1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;ZD1839
CAS NO: 184475-35-2
Molecular Weight: 446.9
Molecular Formula: C22H24ClFN4O3
Boiling Point: 586.8±50.0 °C(Predicted)
Melting point: 119-120°C
Density: 1.322±0.06 g/cm3(Predicted)
Appearance: white to beige powder
Purity: >98%
Storage: room temp

Gefitinib CAS 184475-35-2 usages

Gefitinib, identified by its CAS number 184475-35-2, is a pharmaceutical drug employed for the therapeutic management of specific cancer variants, predominantly non-small cell lung cancer (NSCLC). Here are the primary applications of it:

1. Gefitinib is primarily given for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) that contains particular mutations in the epidermal growth factor receptor (EGFR) gene. These genetic alterations increase the cancer cells’ reliance on EGFR signalling for their growth and survival. Gefitinib is a pharmaceutical compound classified as an EGFR tyrosine kinase inhibitor (TKI) that hinders the functioning of EGFR, thereby impeding the proliferation and dissemination of malignant cells.

2. first therapeutic: Gefitinib can be utilised as a first therapeutic choice for individuals diagnosed with NSCLC who have EGFR mutations, especially those with exon 19 deletions or exon 21 (L858R) replacement mutations. It can be utilised either independently or in conjunction with other cancer drugs, such as chemotherapy or other targeted therapies, based on the distinct attributes of the malignancy and unique patient variables.

3. Maintenance Therapy: In certain instances, gefitinib can be employed as a kind of ongoing treatment after the first use of chemotherapy or other medicines that target the EGFR. Maintenance therapy seeks to extend the duration of disease control and postpone the advancement of the disease in patients who have shown positive responses to prior therapies.

4. Gefitinib can be employed as a second-line or subsequent treatment for patients with non-small cell lung cancer (NSCLC) who have seen progression after prior therapies, such as chemotherapy or other epidermal growth factor receptor (EGFR) inhibitors. It can offer a substitute therapy choice for people who cannot endure conventional medicines or whose cancer has gained resistant to other treatments.

5. Clinical Trials: Gefitinib is utilised in clinical trials to assess its efficacy in treating various forms of cancer or in conjunction with other pharmaceuticals or treatment methods. Clinical trials are conducted to evaluate the safety and effectiveness of novel treatment methods and to explore other applications of gefitinib in cancer treatment.

It is crucial to emphasise that gefitinib must only be administered under the guidance of a competent healthcare practitioner with expertise in cancer therapy. Decisions regarding therapy, such as choosing the right therapies and making adjustments to the dosage, should be made by considering individual patient factors, which include the unique characteristics of the cancer, the overall health condition, and the desired treatment outcomes.

WGP has extensive experience in the chemical raw materials industry and possesses a fully developed manufacturing system and logistics supply chain. If you require any type of intermediates, please do not hesitate to contact us as a top priority.
Transit time You will normally receive your parcel within 7-15 working days after shipment (this may be delayed in special circumstances, such as Chinese New Year).
Receiving method Generally we will send the goods by courier or special line, of course, if the goods themselves in the local warehouse have goods, also support self-pickup, depending on the circumstances.
Overseas warehouse We have overseas warehouses in some European countries and Australia, such as Germany, Russia and Australia.
Delivery Method WGP will ship via courier companies such as DHL, FedEx, UPS, TNT or EMS.
About After Sales Within 7 days of your receipt of the goods if you find any problems with the goods (broken packaging, less hair, etc.) please feel free to contact our sales, we will help you deal with it in time.

You may also like…


There are no reviews yet.

Be the first to review “Gefitinib CAS 184475-35-2”

error: Alert: Content is protected !!